Extending the Cure

The Extending the Cure project is a research and consultative effort that frames the growing problem of antibiotic resistance as a challenge in managing a shared societal resource. The inaugural report of Extending the Cure provides an objective evaluation of a number of policies to encourage patients, health care providers, and managed care organizations to make better use of existing antibiotics and to give pharmaceutical firms greater incentives to both develop new antibiotics and care about resistance to existing drugs. It sets the stage for continued research to prevent the impending health crisis of widespread antibiotic resistance.

 

The Extending the Cure project is funded in part by the Robert Wood Johnson Foundation through its Pioneer Portfolio, which supports innovative projects that may lead to breakthrough improvements in health and health care.

Publications

Recent reports have shown the frequency of vancomycin-resistant Enterococcus faecalis (VRE) is higher in Michigan. Do these findings hold up in national data over the 1999-2010...

How has the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) changed in recent years?

Blog

Seven years ago, Everly Macario lost her one and a half year old son to an infection she would later learn was methicillin-resistant Staphylococcus aureus, or MRSA.  Her story, which...

With the unveiling of the new Partnership for Patients Initiative last week and elements of the Affordable Care...

Yesterday, Health and Human Services Secretary Kathleen Sebelius, flanked by leaders of major hospitals, private companies, and medical associations, unveiled ...

Pages

Tools

Normally found on human skin, Staphylococcus aureus can infect wounds and cause life-threatening conditions such as sepsis and pneumonia. Strains of methicillin-resistant S. aureus (MRSA) fail to respond to commonly used antibiotics, making infections more expensive and difficult to treat.
The maps show the geographic spread of K. penumoniae isolates exhibiting resistance to third-generation cephalosporins (G3CRKP) and carbapenems (CRKP) between 1999 and 2010. Resistant phenotypes were more endemic in the Eastern part of the country, particularly the Middle and South Atlantic Census divisions.
The line graphs show the proportion of K. penumoniae isolates that exhibited resistance to carbapenems (CRKP) and third-generation cephalosporins (G3CRKP) across different patient settings between 1999 and 2010. Previous research has shown carbapenem-resistant infections primarily affect critically-ill or bed-ridden patients.
Use of patient-specific culture data to optimize empiric therapy is a cornerstone of rational hospital antibiotic use. The frequency with which cultures are obtained and therapy tailored to results is unknown.
Antimicrobial stewardship programs (ASPs) are hampered by lack of detailed multicenter data on the primary drivers and classes of antibiotic use. We conducted a retrospective study to identify the types and indications for antibiotic prescribing in 6 different acute-care facilities.